Annual CFF
$94.67 M
-$58.34 M-38.13%
December 31, 2023
Summary
- As of February 8, 2025, MRSN annual cash flow from financing activities is $94.67 million, with the most recent change of -$58.34 million (-38.13%) on December 31, 2023.
- During the last 3 years, MRSN annual CFF has fallen by -$135.74 million (-58.91%).
- MRSN annual CFF is now -58.91% below its all-time high of $230.41 million, reached on December 31, 2020.
Performance
MRSN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$23.00 K
-$176.00 K-115.03%
September 30, 2024
Summary
- As of February 8, 2025, MRSN quarterly cash flow from financing activities is -$23.00 thousand, with the most recent change of -$176.00 thousand (-115.03%) on September 30, 2024.
- Over the past year, MRSN quarterly CFF has increased by +$123.00 thousand (+84.25%).
- MRSN quarterly CFF is now -100.01% below its all-time high of $228.89 million, reached on June 30, 2020.
Performance
MRSN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$6.05 M
+$123.00 K+2.07%
September 30, 2024
Summary
- As of February 8, 2025, MRSN TTM cash flow from financing activities is $6.05 million, with the most recent change of +$123.00 thousand (+2.07%) on September 30, 2024.
- Over the past year, MRSN TTM CFF has dropped by -$129.99 million (-95.55%).
- MRSN TTM CFF is now -97.38% below its all-time high of $230.97 million, reached on March 31, 2021.
Performance
MRSN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MRSN Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.1% | +84.3% | -95.5% |
| 3 y3 years | -58.9% | +84.3% | -95.5% |
| 5 y5 years | +8798.0% | +84.3% | -95.5% |
MRSN Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.1% | +48.8% | -100.0% | +84.3% | -96.0% | +2.1% |
| 5 y | 5-year | -58.9% | +48.8% | -100.0% | +84.3% | -97.4% | +11.8% |
| alltime | all time | -58.9% | +8798.0% | -100.0% | +98.6% | -97.4% | +391.2% |
Mersana Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.00 K(-115.0%) | $6.05 M(+2.1%) |
| Jun 2024 | - | $153.00 K(-97.4%) | $5.93 M(-92.5%) |
| Mar 2024 | - | $5.83 M(+6235.9%) | $78.95 M(-16.6%) |
| Dec 2023 | $94.67 M(-38.1%) | $92.00 K(-163.0%) | $94.67 M(-30.4%) |
| Sep 2023 | - | -$146.00 K(-100.2%) | $136.04 M(-7.3%) |
| Jun 2023 | - | $73.18 M(+239.6%) | $146.82 M(+28.6%) |
| Mar 2023 | - | $21.55 M(-48.0%) | $114.17 M(-25.4%) |
| Dec 2022 | $153.02 M(+140.4%) | $41.46 M(+289.7%) | $153.02 M(+9.0%) |
| Sep 2022 | - | $10.64 M(-73.8%) | $140.35 M(+7.8%) |
| Jun 2022 | - | $40.53 M(-32.9%) | $130.18 M(+5.4%) |
| Mar 2022 | - | $60.39 M(+109.7%) | $123.57 M(+94.1%) |
| Dec 2021 | $63.65 M(-72.4%) | $28.80 M(+6119.2%) | $63.65 M(+74.3%) |
| Sep 2021 | - | $463.00 K(-98.6%) | $36.52 M(+1.4%) |
| Jun 2021 | - | $33.92 M(+7085.6%) | $36.00 M(-84.4%) |
| Mar 2021 | - | $472.00 K(-71.7%) | $230.97 M(+0.2%) |
| Dec 2020 | $230.41 M | $1.67 M(-3498.0%) | $230.41 M(+0.6%) |
| Sep 2020 | - | -$49.00 K(-100.0%) | $228.98 M(-0.0%) |
| Jun 2020 | - | $228.89 M(<-9900.0%) | $229.02 M(+4133.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$90.00 K(-139.0%) | $5.41 M(-94.5%) |
| Dec 2019 | $97.70 M(+9082.7%) | $231.00 K(-2987.5%) | $97.70 M(+0.0%) |
| Sep 2019 | - | -$8000.00(-100.2%) | $97.68 M(-0.2%) |
| Jun 2019 | - | $5.28 M(-94.3%) | $97.90 M(+5.3%) |
| Mar 2019 | - | $92.20 M(>+9900.0%) | $93.01 M(+8641.8%) |
| Dec 2018 | $1.06 M(-98.4%) | $211.00 K(+1.0%) | $1.06 M(+21.7%) |
| Sep 2018 | - | $209.00 K(-46.3%) | $874.00 K(-98.8%) |
| Jun 2018 | - | $389.00 K(+52.5%) | $71.31 M(+3.0%) |
| Mar 2018 | - | $255.00 K(+1114.3%) | $69.25 M(+1.0%) |
| Dec 2017 | $68.60 M(+17.7%) | $21.00 K(-100.0%) | $68.60 M(-0.0%) |
| Sep 2017 | - | $70.64 M(-4345.3%) | $68.60 M(-3401.3%) |
| Jun 2017 | - | -$1.66 M(+315.0%) | -$2.08 M(-103.6%) |
| Mar 2017 | - | -$401.00 K(-1770.8%) | $57.83 M(-0.7%) |
| Dec 2016 | $58.26 M(+484.9%) | $24.00 K(-164.9%) | $58.26 M(+0.0%) |
| Sep 2016 | - | -$37.00 K(-100.1%) | $58.23 M(-0.1%) |
| Jun 2016 | - | $58.24 M(>+9900.0%) | $58.27 M(>+9900.0%) |
| Mar 2016 | - | $31.00 K | $31.00 K |
| Dec 2015 | $9.96 M | - | - |
FAQ
- What is Mersana Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Mersana Therapeutics?
- What is Mersana Therapeutics annual CFF year-on-year change?
- What is Mersana Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly CFF year-on-year change?
- What is Mersana Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Mersana Therapeutics?
- What is Mersana Therapeutics TTM CFF year-on-year change?
What is Mersana Therapeutics annual cash flow from financing activities?
The current annual CFF of MRSN is $94.67 M
What is the all time high annual CFF for Mersana Therapeutics?
Mersana Therapeutics all-time high annual cash flow from financing activities is $230.41 M
What is Mersana Therapeutics annual CFF year-on-year change?
Over the past year, MRSN annual cash flow from financing activities has changed by -$58.34 M (-38.13%)
What is Mersana Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MRSN is -$23.00 K
What is the all time high quarterly CFF for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly cash flow from financing activities is $228.89 M
What is Mersana Therapeutics quarterly CFF year-on-year change?
Over the past year, MRSN quarterly cash flow from financing activities has changed by +$123.00 K (+84.25%)
What is Mersana Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MRSN is $6.05 M
What is the all time high TTM CFF for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM cash flow from financing activities is $230.97 M
What is Mersana Therapeutics TTM CFF year-on-year change?
Over the past year, MRSN TTM cash flow from financing activities has changed by -$129.99 M (-95.55%)